GlassScriptPhysician profile
Amanda Nizam
NPI 1902269137
$45,943.06
in general payments reported to CMS, 2019-2025
11 companies · $38K in 2025
The $38K reported for 2025 was more than what 93% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2022: $1,795 · 2023: $1,186 · 2024: $4,508 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Food and Beverage: $3,845 · Honoraria: $1,868 · Travel and Lodging: $1,025 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,020 · Entertainment: $19.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,232.50 |
| Food and Beverage | $3,844.59 |
| Honoraria | $1,867.50 |
| Travel and Lodging | $1,024.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,020.00 |
| Entertainment | $19.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $32,632.50 | 2025 | |
| Astellas Pharma Global Development | $3,198.49 | 2023-2025 | Padcev |
| Pfizer INC. | $2,912.45 | 2024-2025 | |
| Astellas Pharma US INC | $2,366.45 | 2019-2025 | Padcev, Xtandi |
| Aveo Pharmaceuticals, INC. | $2,271.44 | 2022-2025 | Fotivda |
| Astrazeneca Pharmaceuticals LP | $1,185.94 | 2023-2025 | Lynparza, Tagrisso |
| Seagen INC. | $470.14 | 2022-2023 | Padcev |
| Exelixis INC. | $377.68 | 2023-2025 | Cabometyx |
| Gilead Sciences, INC. | $325.88 | 2023-2024 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $123.11 | 2022 | |
| Astellas Pharma Europe LTD | $78.98 | 2025 | Vyloy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Nizam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.